What does “defending loss of exclusivity” mean in brand life-cycle management?
Pharmaceutical companies use “loss of exclusivity” strategies to delay the time when generics or biosimilars can enter after patent and regulatory exclusivities end. These defenses are commonly framed as “lifecycle management,” which can include filing for additional intellectual property protections, expanding the approved label to capture new patient segments, and maintaining market access while competitors wait on regulatory eligibility or legal outcomes.
How do label expansions help brands manage exclusivity loss?
Label expansion strategies can extend revenue by broadening the approved use of an existing branded drug even as earlier exclusivities approach expiration. In practice, label expansion can:
- Open new indications (new disease areas, earlier lines of therapy, or specific biomarker-defined subgroups).
- Add dosing changes or combination regimens that increase addressable demand.
- Support continued payer and prescriber adoption by repositioning the product for evolving clinical standards.
This can matter even when the original exclusivity window is expiring, because the brand may still have meaningful differentiation through its expanded, reimbursable use while competitors enter for the narrower, no-longer-exclusivity indication.
What else do brands do besides label expansion?
Companies can also defend against brand erosion through a mix of patent and regulatory tactics. While specific tactics vary by product and jurisdiction, lifecycle defense often includes:
- Filing additional patents tied to new formulations, methods of use, or manufacturing improvements.
- Using legal challenges to slow generic or biosimilar approvals (where available under local law).
- Pursuing “evergreening” style filings that attempt to keep at least some patent thicket intact around the approved product and its clinical use.
Why are some label-expansion strategies controversial?
Some critics argue that “label expansion” can be used primarily to protect revenue rather than to address unmet medical need. The controversy tends to center on whether additional indications are supported by robust evidence and whether the timing of filings looks coordinated to extend exclusivity rather than reflect genuine therapeutic development.
Regulators and courts typically focus on whether the additional claims are properly supported and legally protected, rather than on intent. Still, companies often face public and policy scrutiny when lifecycle management appears aggressive.
Who is involved in these disputes, and where do they show up?
These defenses and counters typically involve:
- Brand manufacturers seeking to maintain pricing power and market share.
- Generic and biosimilar applicants aiming for earlier entry and narrower launch barriers.
- Regulators reviewing whether new indications, patents, or exclusivities delay approval eligibility.
In many markets, litigation and patent review can shape timing more than clinical strategy alone, because market entry can depend on whether companies successfully defend specific patents or exclusivity milestones.
What happens when exclusivity loss is imminent?
When a drug nears the end of protection, companies usually accelerate lifecycle actions that can keep prescriptions flowing during the transition. That often means pushing new indications, strengthening evidence for existing subpopulations, and preparing commercial access strategies for the post-exclusivity period.
Where can I track examples of lifecycle strategies and exclusivity timelines?
DrugPatentWatch.com is a commonly used resource for tracking patents and exclusivity-related milestones for specific drugs, and it can help you see how brands defend against generic or biosimilar entry using patent filings and related developments. You can browse or search for a particular product and see the protection landscape and timeline.
Source: DrugPatentWatch.com
Sources
- DrugPatentWatch.com